COVID-19 Antigen Rapid Test Cassette (Colloidal Gold)

English
[VD) C
For professional use only.
For in vitro diagnostic use only

## [INTENDED USE]

The COVID-19 Antigen Rapid Test Cassette is a lateral flow immunoassay intended for the qualitative detection SARS-CoV-2 nucleocapsid antigens in nasopharyngeal swab and oropharyngeal swab from individuals who are suspected of COVID-19 by their healthcare provider.
Results are for the identification of SARS-CoV-2 nucleocapsid antigen. Antigen is generally detectable in nasopharyngeal swab and oropharyngeal swab during the acute phase of infection. Positive results indicate the presence of viral antigens, but clinical correlation with patient history and other diagnostic information is necessary to determine infection status. Positive results do not rule out bacterial infection or co-infection with other viruses. The agent detected may not be the definite cause ofdisease.
Negative results do not rule out SARS-CoV-2 infection and should not be used as the sole basis for treatment or patient management decisions, including infection control decisions. Negative results should be considered in the context of a patient's recent exposures, history and the presence of clinical signs and symptoms consistent with COVID-19, and confirmed with a molecular assay, if necessary for patient management.
The COVID-19 Antigen Rapid Test Cassette is intended for use by trained clinical laboratory personnel specifically instructed and trained in vitro diagnostic procedures.

## [SUMMARY]

The novel coronaviruses (SARS-CoV-2) belong to the $\beta$ genus. COVID-19 is an acute respiratory infectious disease. People are generally susceptible. Currently, the patients infected by the novel coronavirus are the main source of infection; asymptomatic infected people can also be an infectious source. Based on the current epidemiological investigation, the incubation period is 1 to 14 days, mostly 3 to 7 days. The main manifestations include fever, fatigue and dry cough. Nasal congestion, runny nose, sore throat, myalgia and diarrhea are found in a few cases

## [PRINCIPLE]

COVID-19 Antigen Rapid Test Cassette is an immunoassay based on the principle of the double antibody-sandwich technique. The COVID-19 Antigen Rapid Test Cassette is designed to detect nucleocapsid antigen from the SARS-CoV-2 in nasopharyngeal swab and oropharyngeal swab, from patients who are suspected of COVID-19 by their healthcare provider. During testing, a specimen migrates upward by capillary action. The SARS-CoV-2 antigens if present in the specimen will bind to the antibody conjugates. The immune complex is then captured on the membrane by the pre-coated SARS-Co-2 nuclenocapsid protein monoclonal antibody, and a visible colored line will show up in the test line region indicating a positive result. In the absence of SARS-CoV-2 antigens, a colored line will not form in the test line region indicating a negative result.
To serve as a procedural control, a colored line will always appear at the control line region, indicating that proper volume of specimen has been added and membrane wicking has occurred.

## [WARNINGS AND PRECAUTIONS]

- For in vitro diagnostic use only
- For healthcare professionals and professionals at point of caresites.
- Do not use this product as the sole basis to diagnose or exclude

SARS-CoV-2 infection or to inform infection status of COVID-19

- Do not use after the expiration date
- Please read all the information in this leaflet before performing the test.
- The test cassette should remain in the sealed pouch until use.
- All specimens should be considered potentially hazardous and handled in the same manner as an infectious agent.
- The used test cassette should be discarded according to federal, state and local regulations.


## [COMPOSITION]

The test cassette contains a membrane strip coated with anti-SARS-CoV-2 nuclenocapsid protein monoclonal antibody on the $T$ test line, and a dye pad which contains colloidal gold coupled with SARS-CoV-2 nuclenocapsid protein monoclonal antibody.
The quantity of tests was printed on thelabeling.
Materials Provided

- Test Cassette
- Extraction Tube
- Sterilized Swab
- Dropper Tip
- Extraction Reagent
- Work Station
- Package Insert

Materials Required But Not Provided

- Timer


## [STORAGE AND STABILITY]

- Store as packaged in the sealed pouch at temperature $\left(4-30^{\circ} \mathrm{C}\right.$ or $40-$ $86^{\circ} \mathrm{F}$ ). The kit is stable within the expiration date printed on the labeling.
- Once open the pouch, the test should be used within one hour. Prolonged exposure to hot and humid environment will cause product deterioration.
- The LOT and the expiration date were printed on the labeling.


## [SPECIMEN]

Specimens obtained early during symptom onset will contain the highest viral titers; specimens obtained after five days of symptoms are more likely to produce negative results when compared to an RT-PCR assay. Inadequate specimen collection, improper specimen handling and/or transport may yield a falsely negative result; therefore, training in specimen collection is highly recommended due to the importance of specimen quality for generating accurate test results.

## Sample Collection

## Nasopharyngeal Swab Sample

Insert minitip swab with a flexible shaft (wire or plastic) through the nostril parallel to the palate (not upwards) until resistance is encountered or the distance is equivalent to that from the ear to the nostril of the patient indicating contact with the nasopharynx. Swab should reach depth equal to distance from nostrils to outer opening of the ear. Gently rub and roll the swab. Leave swab in place for several seconds to absorb secretions. Slowly remove swab while rotating it. Specimens can be collected from both sides using the same swab, but it is not necessary to collect specimens from both sides if the minitip is saturated with fluid from the first collection. If a deviated septum or blockage creates difficulty in obtaining the specimen from one nostril, use the same swab to obtain the specimen from the othernostril.
(The picture is for references only, please refer to the material object.)

## [TEST PROCEDURE]

Allow the test device and specimens to equilibrate to temperature $\left(15-30^{\circ} \mathrm{C}\right.$ or $59-86^{\circ} \mathrm{F}$ ) prior to testing.

1. Remove the test cassette from the sealed pouch.
2. Reverse the specimen extraction tube, holding the specimen extraction tube upright, transfer 3 drops (approximately $100 \mu \mathrm{~L}$ ) to the specimen well(S) of the test cassette, then start the timer. See illustration below.
3. Wait for colored lines to appear. Interpret the test results at 15 minutes. Do not read results after 20 minutes.

(The picture is for references only, please refer to the material object.)

## [INTERPRETATION OF RESULTS]



Positive Negative Invalid
Positive:*Two lines appear. One colored line should be in the control region (C), and another apparent colored line adjacent should be in the test region (T). Positive for the presence of SARS-CoV-2 nucleocapsid antigen. Positive results indicate the presence of viral antigens but clinical correlation with patient history and other diagnostic information is necessary to determine infection status Positive results do not rule out bacterial infection or co-infection with other viruses. The agent detected may not be the definite cause of disease
Negative: One colored line appears in the control region (C). No line appears in the test region (T). Negative results are presumptive. Negative test results do not preclude infection and should not be used as the sole basis for treatment or other patient management decisions, including infection control decisions, particularly in the presence of clinical signs and symptoms consistent with COVID-19, or in those who have been in contact with the virus. It is recommended that these results be confirmed by a molecular testing method, if necessary, for patient management.
Invalid: Control line fails to appear. Insufficient specimen volume or incorrect procedural techniques are the most likely reasons for control line failure. Review the procedure and repeat the test using a new test cassette. If the problem persists, discontinue using the lot immediately and contact your local distributor

## [QUALITY CONTROL]

A procedural control is included in the test. A colored line appearing in the control region (C) is considered an internal procedural control. It confirms sufficient specimen volume, adequate membrane wicking and correct procedural technique.
Control standards are not supplied with this kit. However, it is recommended that positive and negative controls be tested as good laboratory practice to confirm the test procedure and to verify proper test performance.

## [LIMITATIONS]

- The COVID-19 Antigen Rapid Test Cassette is limited to provide a qualitative detection. The intensity of the test line does not necessarily correlate to the concentration of the antigen of the specimens
- Negative results do not preclude SARS-CoV-2 infection and should not be used as the sole basis for patient management decisions.
- A physician must interpret the results in conjunction with the patient's history, physical findings, and other diagnostic procedures
- A negative result can occur if the quantity of antigens for the SARS-$\mathrm{CoV}-2$ virus present in the specimen is below the detection threshold of the assay, or the virus has undergone minor amino acid
mutation(s) in the target epitope region recognized by the monoclonal antibodies utilized in the test.
- Proper specimen collection is critical, and failure to follow the procedure may give inaccurate results. Improper specimen collection, improper specimen storage or repeated freezing and thawing of specimens can lead to inaccurate results.


## [PERFORMANCE CHARACTERISTICS]

## Limit of Detection (Analytical sensitivity)

The Limit of Detection (LoD) of the COVID-19 Antigen Rapid Test Cassette is $5 \times 10^{2.67} \mathrm{TCID}_{50} / \mathrm{mL}$ (cultured SARS-CoV-2 virus).
Cross Reactivity (Analytical specificity)

Cross reactivity with following Virus or Bacteria culture with certain concentration has been studied. The results were found negative when tested with the COVID-19 Antigen Rapid Test :

| Virus/Bacteria | Concentration | Results |
| :--- | :---: | :---: |
| Influenza A (H1N1) | $1 \times 10^{6} \mathrm{PFU} / \mathrm{mL}$ | - |
| Influenza A (H3N2) | $1 \times 10^{6} \mathrm{PFU} / \mathrm{mL}$ | - |
| Influenza B (Yamagata) | $1 \times 10^{6} \mathrm{PFU} / \mathrm{mL}$ | - |
| Influenza B (Victoria) | $1 \times 10^{6} \mathrm{PFU} / \mathrm{mL}$ | - |
| Adenovirus | $1 \times 0^{6} \mathrm{PFU} / \mathrm{mL}$ | - |
| Human metapneumovirus | $1 \times 0^{6} \mathrm{PFU} / \mathrm{mL}$ | - |
| Parainfluenza virus | $1 \times 0^{6} \mathrm{PFUUL}$ | - |
| Respiratory syncytial virus | $1 \times 0^{6} \mathrm{PFU} / \mathrm{mL}$ | - |
| Streptococcus pyogenes | $1 \times 0^{7} \mathrm{CFU} / \mathrm{mL}$ | - |
| Candida albicans | $1 \times 10^{7} \mathrm{CFU} / \mathrm{mL}$ | - |
| Mycoplasma pneumoniae | $1 \times 0^{7} \mathrm{CFU} / \mathrm{mL}$ | - |
| Chlamydia pneumoniae | $1 \times 0^{7} \mathrm{CFU} / \mathrm{mL}$ | - |
| Legionella pneumophila | $1 \times 0^{7} \mathrm{CFU} / \mathrm{mL}$ | - |
| Human coronavirus 229E | $1 \times 0^{6} \mathrm{PFVU} / \mathrm{mL}$ | - |
| Human coronavirus OC43 | $1 \times 0^{6} \mathrm{PFUU} / \mathrm{mL}$ | - |
| Human coronavirus NL63 | $1 \times 0^{6} \mathrm{PFVU} / \mathrm{mL}$ | - |
| Human coronavirus HKU1 | $1 \times 10^{6} \mathrm{PFU} / \mathrm{mL}$ | - |

## Clinical Performance

To estimate the clinical performance between the COVID-19 Antigen Rapid Test Cassette and the PCR comparator, 628 nasopharyngeal swab were collected from patients who were suspected of COVID-19.
Summary data of COVID-19 Antigen Rapid Test by nasopharyngeal swab as below:

| COVID-19 Antigen |  | RT-PCR |  | Total |
| :---: | :---: | :---: | :---: | :---: |
|  |  | Positive | Negative |  |
|  | Positive | 172 | 0 | 172 |
| HEO® | Negative | 3 | 453 | 456 |
|  |  | 175 | 453 | 628 |

Positive Percent Agreement (PPA)=98.28\% (172/175), (95\%CI:95.08\% ~ 99.41\%)

Negative Percent Agreement (NPA) $=100 \%$ (453/453), (95\%CI: 99.15\%~ 100\%)

Hangzhou Heo Technology Co.,Ltd.
Address:Room201, Building 3, No. 2073 Jinchang Road, Liangzhu Street, Yuhang District, Hangzhou, China Postcode: 311113 Tel:0086-571-87352763 E-mail:52558565@qq.com

Sino Bruecke Consulting GmbH
79100 Freiburg, Germany
E-mail: max.sbc@gmail.com Tel: +49 76115428189

## Index of Symbol

Do not reuse
Store between $4-30^{\circ} \mathrm{C}$

## Caution

Use by
Keep away from sunlight
Manufacturer
IVD For in vitro diagnostic use onlyConsult instructions for use

## LOT Lot number

 Contains sufficient for $<n>$ tests Keep dryDo not use if package is damagedAuthorized representative in the European Community

## ( $€$ The product meets the basic requirements of

 European in vitro. diagnostic medical devices directive $98 / 79 / E C$Version
Effective Date:

